Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2004

View Archived Issues

Korean team describes antitumor agents targeting Wnt-signaling pathways

Gilead claims new anti-HBV/HDV agents

Dual PDE3 inhibitors/beta-AR antagonists and their use in heart failure therapy

Novel DPP-IV inhibitors in early development at Boehringer Ingelheim

AstraZeneca researchers prepare and test new PTP1B inhibitors

Novel weight loss regulators identified by Millennium scientists

New glucagon receptor antagonists covered by Merck patent

Two new selective thiadiazolidinones for Alzheimer's reported by NeuroPharm researchers

PBI-1402: a hematopoietic growth stimulant and chemoprotective agent

Novel, orally active TNF-alpha inhibitor BLX-1028 shows effectiveness in murine arthritis model

In vivo inhibition of brain Abeta level by beta-secretase inhibitor

Antegren BLA for MS accepted for review

Results of Chinese study of VGV-1 in HIV patients

Canadian NDS filing for GlucaGen

Antisoma gains rights to BC1-IL12

Access Pharmaceuticals expands OraDisc development activities

IND approval for Penecure phase I/II trial

Intercell's phase II study of hepatitis C vaccine meets endpoints

INNOVATION study of Micardis completes enrollment

URSO 500 mg approved for primary biliary cirrhosis

Results from six-month study of exenatide

Mylan Laboratories to acquire King Pharmaceuticals

FDA accepts for review Xibrom NDA

Defense Appropriations Bill dedicates funding to Avant's anthrax/plague vaccine

Promising antitumor activity reported for DRF-1042 in patients with refractory solid tumors

A recombinant vaccine confers protection against West Nile disease in hamsters

Lower incidence of levodopa-induced dyskinesia found with sarizotan in PD patients